Júlí 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics og GenScript ProBio eru að undirrita samning um þróun og framleiðslu á plasmíð- og veiruferjum fyrir fyrstu leiðslu ACT Therapeutics Advanced CAR-T Platform (ACT vettvangs), sem einnig verður falið að framleiða hráefni. fyrir síðari leiðslur ACT Therapeutics. Samningurinn mun ná til framleiðslu á plasmíðum og vírusferjum fyrir fyrstu leiðslu ACT Therapeutics Advanced CAR-T pallsins.
Sem afleiðing af þessum samningi hefur GenScript ProBio verið hækkaður í stöðu alþjóðlegs samstarfsaðila sem getur stutt ACT palla fyrir ACT meðferðir.
ACT vettvangurinn er næstu kynslóðar frumu- og genameðferðartækni sem miðar á krabbameinsmótefnavaka með því að setja gen sem eru hönnuð til að miða á þá mótefnavaka inn í ónæmisfrumur. Þessi gen berast inn í ónæmisfrumur með notkun vírusferja. GenScript ProBio býr yfir hágæða vírusferjaferlisþróun og þjónustuvettvangi fyrir GMP framleiðslu, hvort tveggja er nauðsynlegt fyrir þróun frumu- og genameðferðar.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing krabbamein í blóði. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, forstjóri GenScript ProBio, sagði: "Við erum mjög ánægð með að vinna með ACT meðferðum í stefnumótandi samstarfi og við hlökkum til að styðja ACT vettvang ACT Therapeutics sem alþjóðlegan samstarfsaðila í gegnum uppsafnaða tækni okkar."
Seogkyoung-Kong, forstjóri ACT Therapeutics, sagði: „Við höfum lokið undirbúningi fyrir að ACT vettvangurinn komi fram á heimsvísu með stefnumótandi samstarfi við GenScript ProBio. Við munum flýta fyrir þróun meðferða sem miða að eldföstum og óleysanlegum föstum krabbameinum.“
Um GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Í átt að markmiðinu „Nýsköpun í gegnum samvinnu“, er GenScript ProBio skuldbundið til að hjálpa viðskiptavinum að stytta tímalínuna fyrir þróun líffræðilegra lyfja frá uppgötvun til markaðssetningar, lækka verulega R&D kostnað og byggja upp heilbrigðari framtíð.
